PMID- 35117740
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220205
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 9
IP  - 5
DP  - 2020 May
TI  - Fatal interstitial lung disease associated with a series of tyrosine kinase 
      inhibitors treatment in a non-small cell lung cancer patient: a case report.
PG  - 3762-3765
LID - 10.21037/tcr.2020.03.76 [doi]
AB  - Tyrosine kinase inhibitors have significantly improved outcomes for non-small 
      cell lung cancer patient. However, notwithstanding the favorable clinical 
      effects, preclinical toxicity and clinical adverse effects (AEs) inevitably 
      appeared. The impact on safety and degree of toxicity of these promising 
      therapies is not well characterized in patients only with targeted therapy 
      without any chemo- or radiotherapy. We report a case of a non-small cell lung 
      cancer patient who was treated a series of tyrosine kinase inhibitors, including 
      gefitinib, osimertinib, cabozantinib and anlotinib. However, the patient 
      progressively developed into an explosive interstitial pneumonia and died. It is 
      therefore necessary to monitor non-small cell lung cancer patients with tyrosine 
      kinase inhibitors or with pre-existing interstitial lung disease (ILD) very 
      closely as they are at high risk of developing fatal interstitial lung disease.
CI  - 2020 Translational Cancer Research. All rights reserved.
FAU - Han, Ting
AU  - Han T
AD  - Department of Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong 
      University, Shanghai 200127, China.
FAU - Hu, Jiong
AU  - Hu J
AD  - Department of Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong 
      University, Shanghai 200127, China.
FAU - Shi, Yongheng
AU  - Shi Y
AD  - Department of Pathology, Renji Hospital, School of Medicine, Shanghai Jiaotong 
      University, Shanghai 200127, China.
FAU - Wang, Liwei
AU  - Wang L
AD  - Department of Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong 
      University, Shanghai 200127, China.
FAU - Jiao, Feng
AU  - Jiao F
AD  - Department of Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong 
      University, Shanghai 200127, China.
LA  - eng
PT  - Case Reports
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8798260
OTO - NOTNLM
OT  - Tyrosine kinase inhibitors (TKIs)
OT  - case report
OT  - interstitial lung disease (ILD)
OT  - interstitial pneumonia
OT  - non-small cell lung cancer (NSCLC)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tcr.2020.03.76). The authors have 
      no conflicts of interest to declare.
EDAT- 2020/05/01 00:00
MHDA- 2020/05/01 00:01
PMCR- 2020/05/01
CRDT- 2022/02/04 05:51
PHST- 2019/12/09 00:00 [received]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2022/02/04 05:51 [entrez]
PHST- 2020/05/01 00:00 [pubmed]
PHST- 2020/05/01 00:01 [medline]
PHST- 2020/05/01 00:00 [pmc-release]
AID - tcr-09-05-3762 [pii]
AID - 10.21037/tcr.2020.03.76 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2020 May;9(5):3762-3765. doi: 10.21037/tcr.2020.03.76.